FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W303706> ?p ?o ?g. }

• W303706 abstract "Once again, members of Congress have the Food and Drug Administration in their crosshairs. In 2007, their target was the FDA’s perceived failures in terms of drug safety—resulting in the biggest FDA reform bill in decades. As the agency tries to put last year’s drug safety concerns behind it, it must now contend with House and Senate concerns about off-label drug use.Representative Henry Waxman (D-Calif.), chairman of the House Oversight and Investigations Committee, wants the FDA to delay issuing draft guidance on distributing pharmaceutical company promotional literature dealing with off-label use. Senator Charles Grassley (R-Iowa), the top Republican on the Senate Finance Committee, has asked three manufacturers of antipsychotic agents about their off-label promotion of their leading atypical antipsychotics for dementia, which the FDA has approved for psychosis and schizophrenia.Off-label drug use, of course, is permissible; the problem is whether pharmaceutical companies can market drugs to physicians and other medical personnel for non-approved uses. Until 1997, that practice was generally illegal, but in that same year, Congress passed a law allowing legal off-label marketing if certain conditions were met. That “safe harbor” expired on September 30, 2006, and drug companies are chomping at the bit to get that exception renewed.In October 2007, the FDA prepared a draft guidance explaining what it would do.1 However, in a letter to FDA Commissioner Andrew von Eschenbach, MD, Representative Waxman urged him not to go forward with this “ill-advised” guidance.Waxman has two concerns. First, he thinks drug companies should be required to obtain the FDA’s permission before they may disseminate medical journal articles promoting the off-label use of approved drugs; the 1997 exception included this. Second, without the FDA’s agreement, he thinks that drug companies will have no incentive for conducting clinical trials supporting new uses of their products when they can “short-circuit FDA review,” tilt less-than-rigorous trials to “deliver positive results,” and then use the findings to influence prescribing patterns.However, the concerns of both Waxman and Grassley (who opposes the off-label overuse of atypical antipsychotic drugs in nursing homes) are focused on the wrong end of the pipeline; that is, the focus should be on information going out to physicians, not on the physicians receiving the information. Off-label use is vital to many patient groups, and the benefits in those cases often outweigh the risks. However, using drugs in an off-label fashion can present dangers to patients, and the effectiveness of any drug or class of drugs used this way is far from ensured. But it is the physician who is the critical link here, not the drug company.As for the FDA’s draft guidance,1 no one could read it and say that the agency is making life easy for pharmaceutical companies. There are more hurdles to sending out promotional literature than there are on a steeplechase course. For example, a journal or online article cannot be published if the content is “inconsistent with the weight of credible evidence;” it cannot run counter to what has been found in other, similar clinical investigations. If an article contradicts the results of only one other article, that previously published dissenting article would have to be distributed at the same time. And there is more, much more.If the FDA enforces these requirements, drug companies would probably not be sending around dubious articles based on bogus clinical trials, which is Waxman’s concern. The bigger risk is that physicians might not pay close enough attention to the risks of off-label use, which can be substantial. These risks come into play in connection with atypical antipsychotic agents, which are Grassley’s concern.In the October 2007 issue of P&T, David A. Casey, MD, reviewed the black-box warnings that the FDA requires for the labeling of atypical antipsychotic agents. He stated: Combined with the lack of an FDA indication, the warnings call for a special focus on documentation, informed consent, and monitoring for all patients with dementia who are taking atypical antipsychotic drugs.2Medical professionals must pay very careful attention to the off-label use of atypical antipsychotic drugs. Peter V. Rabins, MD, MPH, a psychiatry professor at Johns Hopkins School of Medicine, chaired the American Psychiatric Association’s work group, which published a practice guideline last fall.3 In an interview, he emphasized that non-pharmacological interventions should be tried first for agitated or aggressive nursing-home patients with Alzheimer’s disease or dementia unless these patients pose a clear danger to themselves or others. If those interventions don’t work, antipsychotic agents can be “modestly effective,” he said.Dr. Rabins added that the question of whether antipsychotic agents are being overused in nursing homes is an important one. He explained: I don’t think there is enough scientific evidence to say they are overused. There is good evidence that even when they are appropriately used, the dose can often be lowered or the drug can be discontinued after several months.Rather than alter a pretty toughly worded FDA guidance document, Congressmen Waxman, Grassley, and others who are worried about the overuse of off-label drugs might think about requiring physicians to sign off on an authorization before they prescribe them; they could simply check a box on a script. Signing off would commit doctors to seeing how their patients are handling the drug every few days or every few weeks, and it would confirm that the physicians themselves understand the risks of that prescription and have explained these risks to the patient and family. The American Medical Association would go bonkers, of course, but maybe just raising the possibility means that the message would get out: that off-label prescribing is serious business." @default.
• W303706 created "2016-06-24" @default.
• W303706 creator A5036235042 @default.
• W303706 date "2008-02-01" @default.
• W303706 modified "2023-09-23" @default.
• W303706 title "Off-label drug promotion now on the table: house and senate voice concerns." @default.
• W303706 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2730077" @default.
• W303706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19750002" @default.
• W303706 hasPublicationYear "2008" @default.
• W303706 type Work @default.
• W303706 sameAs 303706 @default.
• W303706 citedByCount "2" @default.
• W303706 countsByYear W3037062014 @default.
• W303706 crossrefType "journal-article" @default.
• W303706 hasAuthorship W303706A5036235042 @default.
• W303706 hasConcept C108170787 @default.
• W303706 hasConcept C118552586 @default.
• W303706 hasConcept C144024400 @default.
• W303706 hasConcept C144133560 @default.
• W303706 hasConcept C17744445 @default.
• W303706 hasConcept C188313352 @default.
• W303706 hasConcept C199539241 @default.
• W303706 hasConcept C2776412080 @default.
• W303706 hasConcept C2776876202 @default.
• W303706 hasConcept C2780494398 @default.
• W303706 hasConcept C2780849931 @default.
• W303706 hasConcept C3018890749 @default.
• W303706 hasConcept C3019878999 @default.
• W303706 hasConcept C36289849 @default.
• W303706 hasConcept C545542383 @default.
• W303706 hasConcept C71924100 @default.
• W303706 hasConcept C83009810 @default.
• W303706 hasConcept C94625758 @default.
• W303706 hasConcept C98147612 @default.
• W303706 hasConcept C98274493 @default.
• W303706 hasConceptScore W303706C108170787 @default.
• W303706 hasConceptScore W303706C118552586 @default.
• W303706 hasConceptScore W303706C144024400 @default.
• W303706 hasConceptScore W303706C144133560 @default.
• W303706 hasConceptScore W303706C17744445 @default.
• W303706 hasConceptScore W303706C188313352 @default.
• W303706 hasConceptScore W303706C199539241 @default.
• W303706 hasConceptScore W303706C2776412080 @default.
• W303706 hasConceptScore W303706C2776876202 @default.
• W303706 hasConceptScore W303706C2780494398 @default.
• W303706 hasConceptScore W303706C2780849931 @default.
• W303706 hasConceptScore W303706C3018890749 @default.
• W303706 hasConceptScore W303706C3019878999 @default.
• W303706 hasConceptScore W303706C36289849 @default.
• W303706 hasConceptScore W303706C545542383 @default.
• W303706 hasConceptScore W303706C71924100 @default.
• W303706 hasConceptScore W303706C83009810 @default.
• W303706 hasConceptScore W303706C94625758 @default.
• W303706 hasConceptScore W303706C98147612 @default.
• W303706 hasConceptScore W303706C98274493 @default.
• W303706 hasLocation W3037061 @default.
• W303706 hasOpenAccess W303706 @default.
• W303706 hasPrimaryLocation W3037061 @default.
• W303706 hasRelatedWork W144791431 @default.
• W303706 hasRelatedWork W1971259066 @default.
• W303706 hasRelatedWork W1977539743 @default.
• W303706 hasRelatedWork W1988964755 @default.
• W303706 hasRelatedWork W1994689960 @default.
• W303706 hasRelatedWork W2040899889 @default.
• W303706 hasRelatedWork W2085805805 @default.
• W303706 hasRelatedWork W2103928570 @default.
• W303706 hasRelatedWork W2119515435 @default.
• W303706 hasRelatedWork W2162978005 @default.
• W303706 hasRelatedWork W2202917426 @default.
• W303706 hasRelatedWork W2410418524 @default.
• W303706 hasRelatedWork W271851143 @default.
• W303706 hasRelatedWork W3092674780 @default.
• W303706 hasRelatedWork W3158665372 @default.
• W303706 hasRelatedWork W68807753 @default.
• W303706 hasRelatedWork W177650825 @default.
• W303706 hasRelatedWork W178843955 @default.
• W303706 hasRelatedWork W1841428428 @default.
• W303706 hasRelatedWork W2243103427 @default.
• W303706 isParatext "false" @default.
• W303706 isRetracted "false" @default.
• W303706 magId "303706" @default.
• W303706 workType "article" @default.